Chiron Capital Management’s Mereo BioPharma MREO Stock Holding History

Chiron Capital Management’s Portfolio MREO Stock Details MREO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-38	Closed	–	–	302
2020 Q3	$0	Buy	+38	New	+$111	﹤0.01%	503

Other funds holding MREO

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Citadel Advisors

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Alkeon Capital Management

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Chiron Capital Management's MREO Position: Q4 2020 in Review

Chiron Capital Management sold out of Mereo BioPharma (MREO) in Q4 2020, closing a stake of 38 shares.

Chiron Capital Management first reported a position in MREO in Q3 2020 and held it in 1 quarter. The position peaked at $0 in Q3 2020. 47 funds tracked by Wall St. Rank hold MREO as of Q4 2020.

Chiron Capital Management reported no remaining Mereo BioPharma position as of Q4 2020 after selling out during the quarter.
Chiron Capital Management sold 38 Mereo BioPharma shares in Q4 2020.
Chiron Capital Management first reported a position in Mereo BioPharma in Q3 2020 and held it in 1 quarter.
Chiron Capital Management's Mereo BioPharma position peaked at $0 in Q3 2020.
47 funds tracked by Wall St. Rank held Mereo BioPharma as of Q4 2020.

Based on Chiron Capital Management's 13F filing for Q4 2020, filed 5 Mar 2021.